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Abstract
Background—Microbicide gels studied for HIV prevention often are delivered via a single-use
vaginal applicator. Using a contraceptive diaphragm such as the SILCS diaphragm for gel delivery
could have advantages, including lower cost and additional pregnancy prevention.
Study Design—We performed an exploratory, nonblinded, randomized, crossover study among
healthy, sexually active, nonpregnant women. Using BufferGel®, we evaluated three microbicide
delivery methods for gel distribution and retention: SILCS single-sided gel delivery, SILCS
double-sided gel delivery and a vaginal applicator (without SILCS). Magnetic resonance images
were taken at baseline, after gel insertion, and immediately and 6 h after simulated intercourse.
Three women completed all gel delivery methods described in this article.
Results—Magnetic resonance imaging analysis indicated similar gel spread in the vagina among
all three methods. SILCS single-sided gel application resulted in the most consistent longitudinal
coverage; SILCS double-sided gel application was the most consistent in the transverse
dimension.
Conclusions—Gel coverage was similar with all three methods. These results suggest that the
SILCS microbicide delivery system is comparable to vaginal applicators for delivery of gel
products intravaginally.
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1. Introduction
The past decade has fostered the development of microbicides intended to prevent HIV
transmission. A recent microbicide trial demonstrated the ability of a vaginal agent to
prevent HIV and herpes simplex virus type 2 transmission [1,2]. In most studies, the gel is
delivered by a single-use, prefilled vaginal applicator which works well in a research
environment, but may not be appropriate or cost-effective for long-term use of a microbicide
gel [3,4]. Using a contraceptive diaphragm such as the SILCS diaphragm for gel delivery
could have advantages, including lower cost and prevention of unintended pregnancy.
© 2013 Elsevier Inc. All rights reserved.
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The SILCS diaphragm (SILCS), named for SILCS, Inc., an early partner in its development,
is a reusable, single-sized contraceptive barrier that improves on features that limit use and
acceptability of traditional diaphragms. Specifically, SILCS has a contoured spring that
allows it to fit most women comfortably. SILCS acceptability and barrier effectiveness have
been reported elsewhere [5–7]. SILCS is an investigational device not yet approved for use
by any regulatory authority.
One vaginal microbicide currently being studied is an investigational drug, BufferGel®
(BG). BG uses an acidic buffering action to maintain the mild, protective acidity of the
vagina in the presence of semen. The safety of BG has been confirmed [8–10], and
contraceptive efficacy compares well to nonoxynol-9 when used with a diaphragm [11].
Since many microbicide gel studies employ vaginal applicators, little is known about the
impact of an alternative delivery system on gel distribution. A diaphragm could influence
gel retention, distribution and user acceptability; however, if gel delivery from a diaphragm
is acceptable, feasible and comparable to gel delivery from a vaginal applicator, a diaphragm
delivery system could also improve women’s options for dual protection. This study
evaluated how gel delivery with SILCS compares to gel delivery from a traditional vaginal
applicator.
2. Materials and methods
This was an exploratory, nonblinded, randomized, crossover study conducted at the Hospital
of the University of Pennsylvania in Philadelphia, PA, between February 2009 and March
2010. The study was approved by the Institutional Review Board of the University of
Pennsylvania and Program for Appropriate Technology in Health (PATH) Research Ethics
Committee. We used magnetic resonance imaging (MRI) to evaluate gel distribution and
retention.
Women, ages 18 to 45 years, who were sexually active with a male partner in the last year
and not pregnant in the past 10 weeks, were screened and enrolled. All women reported
regular menstrual cycles, were not breastfeeding, had no signs of infection or inflammation
of the genitourinary tract, and had no contraindications to an MRI. Women who were using
an intrauterine device or a vaginal ring for contraception were excluded. Before undergoing
the MRI portion of the study, women were assessed for baseline diaphragm size and
practiced inserting the SILCS. Study staff confirmed the correct placement.
The SILCS diaphragms used in this study were provided by PATH and manufactured by
Molded Rubber Products Corporation (MRPC, Butler, WI). BG was provided by ReProtect,
Inc. (Baltimore, MD). BG was mixed with a contrast agent, gadolinium (Omniscan™, GE
Healthcare), to a dilution of 1:100 to allow visualization by MRI.
2.1. Gel delivery methods and visits
This article reports on microbicide gel delivered by three different gel methods: (A) SILCS
with 5 mL of BG applied to the cervical side of the device, (B) SILCS with 2.5 mL of BG
applied to the cervical side of the device and 2.5 mL inserted directly into the vagina after
the diaphragm was placed and (C) 5 mL of BG inserted into the vagina with the vaginal
applicator (without SILCS). Each participant was assigned a unique and random order in
which the gel delivery methods were tested, which was determined by a randomly generated
number provided by the Investigational Drug Service.
All study visits were conducted around the menstrual cycle. If the participant was sterilized
or using hormonal contraception, she scheduled study visits at any time except during her
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menses. If the participant was not using hormonal contraception, she scheduled her visits
between cycle days 6 through 12. The minimum time between each visit was 4 days since
previous data demonstrated that a 48-h washout period was necessary to no longer detect gel
on the MR images [12].
2.2. MRI procedures
At the first study visit, the baseline MRI was performed, which coincided with an interim
history, a urine pregnancy test and assignment to one of the three gel delivery methods. The
second (presimulation) MRI was performed within 15 min of gel insertion. Next, the
participant was asked to simulate vaginal intercourse (30 thrusts) with a model phallus
(Centaur 2, Northampton, MA) under a standard study protocol [13,14]. After completion, a
third (postsimulation) MRI was performed. Then participants left the clinic and assumed
normal daily activities. They were asked to refrain from vaginal intercourse, and those using
SILCS were instructed to leave it in place until after the last MRI. After 6 h, the participants
returned for the fourth (delayed) MRI. After each MRI, the participants assessed the
acceptability of the gel delivery system being used on that day. Each participant returned for
her next visit no earlier than 4 days later to assess the next gel delivery method. Participants
completed at least three study visits, one for each of the gel delivery methods.
2.3. MRI technique
All MRIs were performed on a 1.5-T system (Sonata, Siemens, Erlanger, Germany)
equipped with anterior and posterior array coils. The MRI technique was similar to that
previously described [13–15]. Baseline imaging included axial and sagittal T2-weighted
imaging, as well as thin-slice volumetric T1-weighted imaging to exclude hemorrhagic
contents in the vagina that could mimic gadolinium-doped gel. After gel/diaphragm
insertion, sagittal T2- and T1-weighted imaging was repeated twice (before and after
simulated intercourse). The sagittal imaging series was then repeated at 6 h.
2.4. Statistical analysis
2.4.1. Sample size determination—In order to detect a 20% difference in surface
coverage between any of the two groups with 80% power, given an alpha of 0.05 and a
correlation coefficient of 0.7, it was determined that we needed six subjects. Mean surface
contact value and standard deviation were calculated using data from a previous study
[14,15]. The crossover design allowed for efficient and accurate evaluation of the
differences among methods since there are within-subject and between-subject comparisons.
In this design, each of the participants acted as her own control.
2.5. Anatomical measurements
MR images were analyzed by a single, blinded observer who read and performed all
specified measurements. All image analyses were performed using a three-dimensional (3D)
workstation (TeraRecon®, Foster City, CA). Vaginal dimensions were assessed on
preinsertion T2-weighted images from method C (vaginal applicator) and have been
previously described [13,15]. The vaginal “linear length” was measured segmentally in the
sagittal plane from the introitus to the posterior fornix. Transverse measurements were taken
from the axial images at five anatomic locations: the posterior vaginal fornix, 1 cm below
the anterior cervix, the vaginal flexure and 1 cm above the introitus. These measurements
were added to create a single “summed” transverse dimension [13–15]. Baseline
measurements are shown in Fig. 1.
During the presimulation, postsimulation and delayed MRIs, the sagittal and longitudinal
measurements were repeated using the T1-weighted images to document gel spread. Oblique
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reformatted planes were created to present the maximal transverse spread at each anatomic
location. The linear extent at any anatomic location was measured as the sum of the separate
continuous linear regions.
Linear surface contact is the sum of the width of gel in the posterior fornix (anterior–
posterior plane) and the transverse gel measurement at the four other demarcated anatomic
sites. Linear spread from the posterior fornix to the introitus was assessed in the sagittal
plane. The linear gel spread measurements (longitudinal and summed transverse) were
divided by similar measurements of the vaginal extent on the preinsertion T2-weighted
images to create percent longitudinal and transverse measurements of gel spread (i.e.,
percent surface contact).
2.6. Statistical methods
Comparisons of linear vaginal gel spread were made using Wilcoxon signed-rank tests since
we could not predict that the data would be normally distributed. SAS (Cary, NC) software
was used for statistical analysis. Analysis included χ2 tests, paired t test and analysis of
variance (ANOVA). Descriptive statistics were employed to provide preliminary data on
acceptability.
3. Results
3.1. Demographic characteristics
Nine women were screened, and six enrolled in the study. They were on average 26 years
old (range 23–32 years). Three of the six participants were Caucasian, two were African
American, and one was Asian. Four of the six participants were using hormonal
contraception during their participation, and all were nulliparous.
3.2. Gel coverage assessment
Initial MRI assessments from the six women in this study showed unexpected results when
using the SILCS diaphragm. There were larger than expected differences between the
SILCS methods A and B when compared to method C (Fig. 2). Based on qualitative data
(not reported here), we surmised that this was due to difficulty with expressing gel from a
sachet which resulted in inconsistent gel volumes introduced into the vagina. Since this was
an exploratory study, we revised the gel packaging, and three women repeated methods A
and B using the modified gel packaging. This additional step ensured that a uniform gel
volume was applied to the SILCS and resulted in MRI scans with more comparable gel
volume in the vagina. The differences between the original gel delivery methods A and B
(identified as Ao and Bo) and the new methods A and B with modified packaging (identified
as An and Bn) were statistically different. The difference was attributable to the poor
functionality of the original gel packaging rather than the ability of the SILCS to deliver the
gel once it was inserted vaginally. Since the gel spread seen with the revised gel packaging
was more consistent with gel images from previous studies, we accepted the revised
packaging as a more reliable method for delivering a consistent gel dose. All six participants
completed 12 MRIs; the three women who repeated methods A and B, each with the
updated gel packaging, underwent 8 additional MRIs for a total of 20 MRIs. Only results
from the new methods (An and Bn) are presented here and will be referred to as methods A
and B from here forward.
Longitudinal and transverse gel coverage assessments for methods A, B and C were
compared at the various study visits and are presented in Table 1. When assessing changes
in gel spread over time, there were four statistically significant differences in gel spread.
First, in method A, as time passed, the transverse gel spread decreased. Second, in method
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B, as time passed, longitudinal gel spread increased. Lastly, in method C, in both the
transverse and longitudinal directions, the gel spread increased with time. Comparisons for
gel spread among the methods, at each specific time point, are presented in Fig. 3. No
statistically significant differences between the absolute spread and percent spread were
found when comparing methods A, B and C at each time point.
3.3. Qualitative pattern of spread
Upon review of 3D MRIs, there were qualitative differences in spread among methods of gel
delivery. The pattern of gel spread using an applicator (Fig. 2-i) was similar to previous
studies [13]. The gel forms an image of the vaginal contour including the projection of the
cervix into the vaginal canal. The gel pattern seen with SILCS, however, conforms to the
shape of the SILCS diaphragm, resulting in an outline of the device. Gel is clearly seen
“inside” the dome of the SILCS and outlining its rim (Fig. 1-iii). Little gel was visible below
the SILCS in method A or B.
3.4. Adverse events
There were no major safety concerns or serious adverse events in the study. One subject
developed a yeast infection that was thought to be related to the study.
4. Discussion
This is the first randomized, prospective study that examines the use of the SILCS
diaphragm as a gel delivery system. Our data demonstrate that there were no detectable
differences between the gel delivery seen with the SILCS diaphragm and that seen with the
vaginal applicator.
The design took advantage of paired comparison in the same women to enhance the ability
to find objective differences in gel deployment among the methods. While it is a small
sample, initial findings indicate that placing the entire volume of gel into the cervical cup
prior to inserting the SILCS diaphragm (method A) provided the most consistent
longitudinal coverage. Method B, where the gel volume was divided between the cervical
side of the SILCS and the lower vagina, provided the most consistent transverse
measurements. There were statistically significant differences in the transverse and
longitudinal gel spread seen when a vaginal applicator was used to administer the gel in
method C. In method C, transverse coverage increased with time, while the longitudinal
coverage peaked after simulated intercourse. It is unclear if these variations are clinically
relevant, and our results support the conclusion that this novel gel delivery system has
similar capabilities as a vaginal applicator.
When comparing methods at each time point, we found that methods using the SILCS
(methods A and B) resulted in higher longitudinal and transverse coverage at the pre- and
postsimulation time points when compared to the vaginal applicator (method C). Since the
transmission of sexually transmitted infections and the risk of pregnancy are highest during
sexual intercourse, we are hopeful that the coverage at pre- and post-intercourse simulation
with the SILCS will be relevant in clinical application.
One qualitative difference noted was the variation of BG spread on MRI among the three
groups. The gel pattern seen when delivered with the SILCS is different than when it is
delivered by a vaginal applicator. It appears that there is “pooling” of gel along the edge of
the SILCS around the cervix. This observation calls into question whether linear methods
are the best descriptor for gel distribution when using devices such as the SILCS.
Quantification of these observations may require development of new measurement models
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to judge the “thickness” and “intactness” of the gel “ring” along the edge of the SILCS,
which in turn could represent a different level of protection.
This study is limited by its small sample size. Unexpected findings required additional data
collection so that only three women (instead of six) completed all gel delivery scenarios
reported here. Notwithstanding, these pilot data are crucial in designing future studies.
The clinical significance of the differences and trends noted in this study needs to be further
elucidated in larger studies. To date, it is unknown if it is optimal to maximize gel
deployment to the transverse, longitudinal or upper aspects of the vagina. However, data
suggest that adequate coverage at the pre- and postsimulation time points are clinically
important in the prevention of pregnancy and infection. Our data show that the use of the
SILCS to deliver gel intravaginally is comparable to the vaginal applicator. It is possible that
once an effective microbicide gel is optimized, its use with the SILCS diaphragm could
maximize dual protection options for women.
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Fig. 1.
Example of linear vaginal measurements from T2-weighted MR image prior to gel insertion.
(i) Axial image of the lower vagina (3 cm above introitus) with segmented linear tracing
along vaginal mucosa. Transverse length at this location was 36 mm. (ii) Sagittal T2-
weighted MR images demonstrating the longitudinal view and measurement of the vagina.
Longitudinal vaginal length was 85 mm. (iii) Sagittal image with linear tracing along
vaginal mucosa around the cervix in an anterior–posterior fashion.
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Fig. 2.
Visualization of the effect of gel volume administration. Maximum intensity projection
images in the anterior–posterior view of the 3D T1-weighted MR images immediately after
gel insertion for one subject. Gadolinium-doped gel is seen as bright areas against dark
tissue background. (i) Gel distribution after applicator administration without SILCS device
(method C). (ii) Gel distribution after split dosing of 2.5 mL each to the cervical and vaginal
sides via method Bo. Note relative paucity of visualized gel (moderately bright areas in
superior aspect of image represent bowel contents). (iii) Gel distribution after split dosing of
2.5 mL to the cervical side of the SILCS and the remaining 2.5 ml inserted using an
applicator (method Bn).
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Fig. 3.
(i) Percentage longitudinal vaginal coverage at three time points. (ii) Percentage transverse
vaginal coverage at three time points. The graphs are shown with error bars representing the
standard deviation. Results may exceed 100% given postsimulation distention.
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